1
|
Attia S, Mahoney MR, Okuno SH, Adkins D, Ahuja HG, Ducker TP, Maples WJ, Ochs L, Wentworth-Hartung NL, Erlichman C, Bailey HH. A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10075] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Jones MW, Zhang C, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Kolesar J, Wims MB, Hernan H, Campbell TC, Traynor AM, Hoang T. Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol 2009; 27:11-6. [PMID: 18668698 DOI: 10.1002/hon.870] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Arsenic trioxide (As(2)O(3)) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As(2)O(3) may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic acid (AA), may potentiate arsenic-mediated apoptosis. This multi-institution phase II study investigated a novel dosing schedule of As(2)O(3) and AA in patients with relapsed or refractory lymphoid malignancies. Patients received As(2)O(3) 0.25 mg/kg iv and AA 1000 mg iv for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2-6. Cycles were repeated every 8 weeks. The primary end point was objective response. In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl-2 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment. Seventeen patients were enrolled between March 2002 and February 2004. The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17). Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%. The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity. Haematologic toxicities were the most commonly reported events in this heavily pre-treated population, and comprised the majority of grade 3 and 4 toxicities. Intracellular depletion of glutathione was not consistently observed during treatment. As(2)O(3) and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies.
Collapse
Affiliation(s)
- J E Chang
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Traynor AM, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Schiller JH. Phase I/II study of exisulind (E) and vinorelbine (V) in elderly patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. M. Traynor
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - J. J. Merchant
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - T. Hoang
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - H. G. Ahuja
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - P. A. Beatty
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - R. M. Hansen
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - G. A. Masters
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - K. R. Oettel
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - G. R. Shapiro
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - J. H. Schiller
- University of Wisconsin Comprehensive Cancer Center, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| |
Collapse
|
5
|
Hoang T, Kim K, Merchant J, Traynor AM, Ahuja HG, Masters GA, McGovern JD, Oettel KR, Sanchez FA, Schiller JH. Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Hoang
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - K. Kim
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - J. Merchant
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - A. M. Traynor
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - H. G. Ahuja
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - G. A. Masters
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - J. D. McGovern
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - K. R. Oettel
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - F. A. Sanchez
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| | - J. H. Schiller
- University of Wisconsin Medical School, Madison, WI; McFarland Clinic, Ames, IA; Wisconsin Oncology Network, Madison, WI; Helen Graham Cancer Center, Newark, DE
| |
Collapse
|
6
|
Abstract
The role of the BCR-ABL fusion gene in the pathogenesis of the chronic phase of chronic myelogenous leukemia (CML) has been well established. Several additional genetic changes have been reported to occur, at varying frequencies, during disease progression to "accelerated" and "blast crisis" phases. The NUP98 gene localized to chromosome band 11p15 has been found at the breakpoints of several distinct chromosomal translocations in patients with both de novo and therapy-related myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). Using combined cytogenetic and molecular analyses, we have found rearrangements of the NUP98 gene in the leukemic cells of two patients with Philadelphia chromosome-positive CML, during disease evolution. As expected, analysis of the t(7;11)(p15;p15) from one of the patients showed an in-frame NUP98-HOXA9 fusion. The fusion points were similar to previously reported NUP98-HOXA9 fusion points from patients with MDS/AML. Our results indicate that the NUP98 gene is an additional, albeit infrequent, genetic target during clonal evolution of CML.
Collapse
MESH Headings
- Chromosome Breakage/genetics
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 2/genetics
- Clone Cells
- Evolution, Molecular
- Female
- Homeodomain Proteins/genetics
- Humans
- Karyotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Membrane Proteins/genetics
- Middle Aged
- Neoplasm Proteins/genetics
- Nuclear Pore Complex Proteins
- Nuclear Proteins/genetics
- Oncogene Proteins, Fusion/genetics
- Translocation, Genetic
Collapse
Affiliation(s)
- H G Ahuja
- Roswell Park Cancer Institute, Department of Medicine, Buffalo, NY, USA.
| | | | | | | |
Collapse
|
7
|
Ahuja HG, Hong J, Aplan PD, Tcheurekdjian L, Forman SJ, Slovak ML. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res 2000; 60:6227-9. [PMID: 11103774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
A t(9;11)(p22;p15) chromosomal translocation was identified in an adult patient with de novo acute myelogenous leukemia. Fluorescence in situ hybridization and Southern blot analysis mapped the 11p15 break-point to the NUP98 gene. Using 3' rapid amplification of cDNA ends, we have identified a chimeric mRNA that fused the NUP98 FXFG repeats in frame to the COOH-terminal portion of the gene encoding the transcriptional coactivators p52 and p75, also known as lens epithelium-derived growth factor (LEDGF). As expected, both NUP98-p52 and NUP98-p75 (LEDGF) chimeric mRNAs were detected by reverse transcription-PCR; however, the reciprocal p52/p75 (LEDGF)-NUP98 fusion mRNA was not detected. Our results demonstrate that this is the most 5' NUP98 fusion reported and reveal a previously unrecognized genetic target, the gene encoding p52/p75 (LEDGF).
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Amino Acid Sequence
- Artificial Gene Fusion
- Base Sequence
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 9
- Growth Substances/genetics
- Humans
- In Situ Hybridization, Fluorescence
- Intercellular Signaling Peptides and Proteins
- Leukemia, Myeloid, Acute/genetics
- Male
- Membrane Proteins/genetics
- Middle Aged
- Molecular Sequence Data
- Nuclear Pore Complex Proteins
- Nuclear Proteins/genetics
- RNA, Messenger/genetics
- Recombinant Fusion Proteins/genetics
- Repetitive Sequences, Nucleic Acid
- Reverse Transcriptase Polymerase Chain Reaction
- Trans-Activators/genetics
- Transcription Factors
- Translocation, Genetic
Collapse
Affiliation(s)
- H G Ahuja
- Depurtment of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
Chromosomal aberrations are frequently associated with therapy-related myelodysplastic syndromes and acute myelogenous leukemia (t-MDS/AML) and are thought to result from exposure to genotoxic drugs, including alkylating agents and DNA topoisomerase II poisons. The NUP98 gene on chromosome band 11p15 is involved in several different chromosomal aberrations that have been associated with t-MDS/AML. We have cloned the translocation breakpoints from two cases of t-MDS harboring a t(11;20)(p15;q11). Sequence analysis of the breakpoints from both cases revealed almost perfectly balanced translocations between NUP98 and TOP1. There were no known recombinogenic sequences identified at or near the breakpoints. However, four bp microduplications present at the translocation crossover points suggested that these translocations may have been initiated by 4 bp staggered double-stranded DNA breaks, which are known to be associated with the action of topoisomerase II. Given the history of patient exposure to topoisomerase II poisons, and the fact that these drugs stabilize staggered breaks with a 4 bp overhang, it seems possible that drug-induced topoisomerase II cleavage and subunit exchange was involved in these translocations. These results suggest that NUP98 is a recurrent target for therapy-related malignancies induced by multiagent chemotherapy, and suggest a role for DNA topoisomerase II poisons in the generation of these translocations. Published 2000 Wiley-Liss, Inc.
Collapse
Affiliation(s)
- H G Ahuja
- Roswell Park Cancer Institute, Department of Medicine, Buffalo, New York
| | | | | |
Collapse
|
9
|
Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 1999; 94:3258-61. [PMID: 10556215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
The NUP98 gene is involved in 3 distinct chromosomal rearrangements, t(7;11)(p15;p15), t(2;11)(q31;p15), and inv(11)(p15q22); all of these NUP98 rearrangements have been identified in the malignant cells of patients with therapy-related acute myelogenous leukemia or myelodysplastic syndrome (t-AML/MDS). Here we report the cloning and characterization of a t(11;20)(p15;q11) translocation from patients with t-MDS. The breakpoint on chromosome 11p15 targets the NUP98 gene and results in the separation of the N-terminal FXFG repeats from the RNA-binding domain located in the C-terminus. The breakpoint on chromosome 20q11 occurs within the gene encoding human DNA topoisomerase I (TOP1). As a result, a chimeric mRNA encoding the NUP98 FXFG repeats fused to the body of DNA topoisomerase I is produced. These results indicate that NUP98 is a recurrent target in therapy-related malignancies, and that TOP1 is a previously unrecognized target for chromosomal translocations.
Collapse
Affiliation(s)
- H G Ahuja
- Departments of Medicine, Pediatrics, and Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | |
Collapse
|
10
|
Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78:3259-68. [PMID: 1683797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The retinoblastoma-susceptibility (Rb) gene is an antioncogene that is frequently altered in retinoblastomas, sarcomas, and some epithelial tumors. We examined the structure of the Rb gene by Southern blotting in 215 cases of leukemias and lymphomas of diverse phenotype and in 15 leukemic cell lines. In selected cases Rb protein expression was examined with specific monoclonal antibodies. Structural abnormalities of the Rb gene with absent protein expression were frequent in all types of human acute leukemia, but were particularly common (27% incidence) in M4 and M5 myeloid leukemia with monocytic differentiation and in Philadelphia chromosome (Ph1)-positive leukemia of lymphoid phenotype (11% to 29% incidence). Changes in Rb were observed early in the transition to acute leukemia in cases of myelodysplastic syndrome and in the accelerated phase of chronic myelocytic leukemia in transition to blast crisis. In one case, molecular changes in Rb could be correlated with leukemia remission and relapse. We conclude that the Rb antioncogene is commonly involved in the evolution of human acute leukemias, particularly in those of a monocytic phenotype and in lymphoid leukemia in which there is an antecedent alteration of the Ph1 chromosome.
Collapse
MESH Headings
- Acute Disease
- Adolescent
- Adult
- Antibodies, Monoclonal
- Blast Crisis/genetics
- Blotting, Southern
- Child
- DNA, Neoplasm/chemistry
- DNA, Neoplasm/genetics
- Gene Expression
- Genes, Retinoblastoma/genetics
- Humans
- Immunoblotting
- Leukemia/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myeloid, Acute/genetics
- Lymphoma/genetics
- Myelodysplastic Syndromes/genetics
- Philadelphia Chromosome
- Polymorphism, Restriction Fragment Length
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
Collapse
|
11
|
Foti A, Ahuja HG, Allen SL, Koduru P, Schuster MW, Schulman P, Bar-Eli M, Cline MJ. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 1991; 77:2441-4. [PMID: 2039825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
A patient with typical Philadelphia chromosome (Ph1)-positive chronic myelocytic leukemia (CML) was studied during sequential phases of disease: (1) initial chronic phase; (2) myeloid blast crisis; (3) second chronic phase; and (4) accelerated disease. A point mutation in the coding sequence of the p53 gene first appeared concomitantly with the blast crisis and then disappeared with the re-establishment of a second chronic phase. The chromosomal concomitant of the molecular alteration was a deletion of 17p. These observations suggest that abnormalities of the p53 anti-oncogene are temporally related to the clinical progression of some cases of CML and are probably responsible for the development of blast crisis in these cases.
Collapse
MESH Headings
- Adult
- Base Sequence
- Blast Crisis/genetics
- Chromosome Deletion
- DNA/blood
- DNA/genetics
- DNA/isolation & purification
- Exons
- Gene Rearrangement
- Humans
- Introns
- Karyotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Male
- Molecular Sequence Data
- Mutation
- Polymerase Chain Reaction/methods
- Tumor Suppressor Protein p53/genetics
Collapse
Affiliation(s)
- A Foti
- UCLA School of Medicine 90024-1678
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Foti A, Bar-Eli M, Ahuja HG, Cline MJ. A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line: a novel mechanism of p53 gene inactivation. Br J Haematol 1990; 76:143-5. [PMID: 2223633 DOI: 10.1111/j.1365-2141.1990.tb07849.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Alterations of the p53 anti-oncogene have recently been found to occur frequently in the blast crisis of chronic myelocytic leukaemia. The p53 gene may be altered by gross structural alterations or by point mutations in the coding sequence. We now report a novel mechanism of gene inactivation in a blast crisis cell line where a mutation in a splice donor site at the 5' end of the fifth intron of the gene interrupts RNA processing and gene expression.
Collapse
Affiliation(s)
- A Foti
- Division of Hematology/Oncology, UCLA School of Medicine 90024-1678
| | | | | | | |
Collapse
|
13
|
Ahuja HG, Testa MP, Cline MJ. Variation in the protein coding region of the human p53 gene. Oncogene 1990; 5:1409-10. [PMID: 1977117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
This report describes a restriction fragment length polymorphism for the enzyme BglII caused by a conserved C to T change at residue 21 of the human p53 gene. This RFLP could potentially be misinterpreted as a rearrangement or a point mutation if paired constitutional tissue is not simultaneously analyzed.
Collapse
Affiliation(s)
- H G Ahuja
- UCLA School of Medicine, Division of Hematology/Oncology 90024-1678
| | | | | |
Collapse
|
14
|
Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75:1684-90. [PMID: 2183888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
DNA from 161 patients with various forms of hematologic malignancies were investigated for mutations in exons 1 and 2 of the N-RAS, K-RAS and Ha-RAS gene by direct sequencing of DNA amplified in vitro by the polymerase chain reaction. Mutations involving either codons 11, 12, or 13 of the N-RAS gene were identified in 18 of the 161 patients. The relative frequencies of N-RAS gene mutations in these hematologic disorders was as follows: acute myelogenous leukemia (AML), 15%; acute lymphoblastic leukemia (ALL), 14%; myelodysplastic syndromes, 24%; and myeloid and lymphoid blast crisis of chronic myelogenous leukemia (CML), 3%. No correlation was observed between the presence of mutations and cytologic features or immunophenotype of these malignancies. Mutations involving codons 12 or 13 were equally prevalent, with a glycine to aspartic acid substitution being the most frequently encountered change. A single T-ALL case had a codon 11 mutation resulting in substitution of alanine with threonine. We failed to find mutations in exons 1 and 2 of the K-RAS or Ha-RAS genes in any case except a single AML with a mutation in codon 61 of the K-RAS gene. Also, no mutations were identified in chronic phase of CML, chronic lymphocytic leukemia. Ph1 positive ALL, non-Hodgkin's lymphoma, Hodgkin's disease, or multiple myeloma. These results indicate that RAS mutations, especially those involving exon 1 of the N-RAS gene, are frequent only in a subset of hematologic malignancies.
Collapse
Affiliation(s)
- H G Ahuja
- Department of Medicine, Jonsson Cancer Center, UCLA School of Medicine 90024-1678
| | | | | | | |
Collapse
|
15
|
Ahuja HG, Foti A, Zhou DJ, Cline MJ. Analysis of proto-oncogenes in acute myeloid leukemia: loss of heterozygosity for the Ha-ras gene. Blood 1990; 75:819-22. [PMID: 1967953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
At least 13 of 34 patients with acute myeloid leukemia (AML) of varying FAB types were heterozygous for a BamHI restriction fragment length polymorphism (RFLP) of the Ha-ras gene on chromosome 11. In 4 of these 13 patients, one allele of the Ha-ras gene was deleted. Two of these cases had an informative heterozygosity for an RFLP on the long arm of chromosome 11. Analysis of these cases indicated that loss of genes from chromosome 11 was restricted to the short arm. In three cases with loss of one Ha-ras gene, the remaining gene had no mutations in critical areas of exons 1 and 2. With the exception of one AML case with amplification of MYC, no gross structural abnormalities in 12 other oncogenes were detected.
Collapse
Affiliation(s)
- H G Ahuja
- Division of Hematology/Oncology, University of California, Los Angeles
| | | | | | | |
Collapse
|
16
|
Abstract
In recent years, a number of non-random chromosomal alterations have been identified in specific populations of acute lymphoblastic leukemic cells of either B-cell or T-cell lineage. The most frequently involved chromosomal sites are 1q, 4q, 6q, 7q, 8q, 9p, 9q, 10q, 11p, 12p, 14q, 19p and 22q. Genes located near frequent breakpoints include c-myc, c-abl and the genes for the T-cell alpha and beta receptors. In addition, approximately 20 other genes potentially involved in the leukemic process are located near less frequently encountered, but consistent, chromosomal breakpoints.
Collapse
|
17
|
Advani SH, Ahuja HG, Gopal R, Nair CN, Saikia TK, Kumar A, Borges AM, Talwalkar GV. T-cell chronic lymphocytic leukaemia. Indian J Cancer 1988; 25:117-27. [PMID: 2976022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
18
|
Advani SH, Ahuja HG, Gopal R, Athanikar N, Nair CN, Saikia T, Nadkarni KS, Kumar A. Clinical and phenotypic heterogeneity in L3-acute lymphoblastic leukaemia. Indian J Cancer 1988; 25:108-13. [PMID: 3263938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
19
|
Ahuja HG, Advani SH, Gopal R, Nair CN, Saikia T, Soman CS, Talwalkar GV. Hairy cell leukaemia: a clinicopathological study. J Assoc Physicians India 1986; 34:689-91. [PMID: 3818513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
20
|
Advani SH, Ahuja HG, Pai MR, Saikia T, Gopal R, Nair CN. Pre-sepsis prophylaxis and empirical treatment of febrile patients with neutropenia in acute leukaemia. J Assoc Physicians India 1986; 34:559-62. [PMID: 3466893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
21
|
Ahuja HG, Advani SH, Gopal R, Nair CN, Saikia T. Acute nonlymphoblastic leukemia in the first of three siblings affected with Fanconi's syndrome. Am J Pediatr Hematol Oncol 1986; 8:347-9. [PMID: 3799935 DOI: 10.1097/00043426-198624000-00017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
22
|
Saikia TK, Ahuja HG, Gopal R, Nair CN, Kamat DM, Pai MR, Advani SH. Outcome of aggressive induction therapy in acute non-lymphocytic leukaemia. J Assoc Physicians India 1985; 33:203-6. [PMID: 4044476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|